Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats
- 22 January 2009
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 204 (2) , 241-250
Abstract
Rationale Dyskinesia affects the majority of levodopa-treated parkinsonian patients within 5–10 years of treatment with levodopa. Clinical and preclinical observations suggest that an increase in serotoninergic transmission can contribute to the appearance of dyskinesias. It is thus conceivable that a modulation of synaptic dopamine (DA) levels induced by the inhibition of serotonin (5-HT) release, as a consequence of 5-HT1A agonists administration, might alleviate dyskinesias. Objective Since 5-HT1A receptors are expressed in the subthalamic nucleus (STN), the aim of the present study was to assess the effect of the intrasubthalamic administration of sarizotan, a compound with full 5-HT1A agonist properties, on levodopa-induced dyskinesias in the 6-hydroxydopamine (6-OHDA) model of parkinsonism. Materials and methods Male Sprague–Dawley rats received a unilateral 6-OHDA administration in the nigrostriatal pathway. A test of apomorphine was performed to evaluate dopamine depletion. One week later, a cannula was implanted in the STN. Animals were treated with levodopa (6 mg/kg, i.p., twice at day) for 22 consecutive days. On day 23, several doses (1 ng, 10 ng, or 1 μg) of sarizotan were administered through the cannula to the STN. The higher doses of sarizotan effectively attenuated all levodopa-induced dyskinesias including axial, limb, and orolingual subtypes. Conclusions These results suggest that the STN is a target structure for the antidyskinetic action of sarizotan and indicate that drug-mediated modulation of STN activity may be an alternative option for the treatment of levodopa-induced dyskinesias in Parkinson’s disease.Keywords
This publication has 70 references indexed in Scilit:
- Preferential loss of serotonin markers in caudate versus putamen in Parkinson's diseaseBrain, 2007
- Investigation of the impact of sarizotan on the pharmacokinetics of levodopaBiopharmaceutics & Drug Disposition, 2007
- Control of the Subthalamic Innervation of the Rat Globus Pallidus by D2/3and D4Dopamine ReceptorsJournal of Neurophysiology, 2006
- The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptorsNeuropharmacology, 2006
- MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulationEuropean Journal of Neuroscience, 2006
- Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian ratsMovement Disorders, 2006
- 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: Action at 5-HT2C, 5-HT4 and 5-HT1A receptorsNeuropharmacology, 2005
- Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPABrain Research, 2005
- L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNAEuropean Journal of Neuroscience, 1998
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989